Abstract
Human epidermal growth factor (EGF), a small polypeptide (6 kDa) with mitogenic properties, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention and healing of sclerotherapy-induced esophageal lesions was investigated in 24 minipigs with surgically induced portal hypertension. In addition, the effect of EGF on intragastric acidity and pharmacokinetics was investigated as possible means to explain its protective mechanism of action. The animals underwent three weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly and for an additional three weeks treated with either placebo or EGF administered paravenously in the esophagus and/or subcutaneously. The subcutaneous treatment with EGF significantly (P<0.05) reduced esophageal stricture and scar formations associated with sclerotherapy. Gastric pH values were significantly (P<0.01) elevated only in animals receiving subcutaneous injections of EGF. Furthermore, the subcutaneous administration of EGF was associated with unexpected prolonged plasma concentration of the peptide. These results suggest a possible clinical value of EGF as an adjunctive treatment with the sclerotherapy.
Similar content being viewed by others
References
Singai AK, Sarin SK, Misra SP, Broor SL: Ulceration after esophageal and gastric variceal sclerotherapy-Influence of sucralfate and other factors on healing. Endoscopy 20:238–240, 1988
Soerensen TIA, Burcharth F, Pedersen ML, Findahl F: Oesophageal stricture and dysphagia after endoscopic sclerotherapy for bleeding. Gut 25:473–477, 1984
Pulanic R, Vrhovac B, Jokic N, Rosandic-Pilas M, Salamon V, Opacic M, Rustemovic N, Korac C, Vucelic B: Prophylactic administration of ranitidine after sclerotherapy of esophageal varices. Int J Clin Pharmacol Toxicol 29:347–351, 1991
Tabibian N, Smith JL, Graham DY: Sclerotherapy-associated esophageal ulcers: Lessons from a double-blind, randomized comparison of sucralfate suspension versus placebo. Gastrointestinal Endoscopy 35:312–315, 1989
Paquet KJ, Koussouris P, Keinath R, Rambach W, Kalk J-F: A comparison of sucralfate with placebo in the treatment of esophageal ulcers following therapeutic endoscopic sclerotherapy of esophageal varices—a prospective controlled randomized trial. Am J Med 91:S147-S150, 1991
Johlin FC, Labrecque DR, Neil GA: Omeprazole heals mucosal ulcers associated with endoscopic injection sclerotherapy. Dig Dis Sci 37:1373–1376, 1992
Gimson A, Polson R, Westaby D, Williams R: Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy. Gastroenterology 99:1829–1831, 1990
Bhargava DK, Garg P: Sclerotherapy associated esophageal ulcers: Omeprazole versus placebo—a double-blind randomized study. Abstract from Second Osaka International Symposium on Gastroenterology, Osaka, Japan. November 1993
Carpenter G, Cohen S: Epidermal growth factor. J Biol Chem 265:7709–7712, 1990
Nexø E, Olsen PS, Poulsen K: Exocrine and endocrine secretion of renin and epidermal growth factor from the mouse submandibular glands. Regul Pept 8:327–334, 1984
Sarosiek J, Feng T, McCallum RW: The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci 302:359–363, 1991
Elder JR, Ganguli PC, Gillispie IE, Gerring EL, Gregory H: Effect of urogastrone on gastric secretion and plasmagastrin levels in normal subjects. Gut 16:887–893, 1975
Goodlad RA, Wilson TJ, Lenton W, Gregory H, Mccullagh KG, Wright NA: Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats. Gut 28:573–582, 1987
Marti U, Burwen SJ, Jones AL: Biological effects of epidermal growth factor, with emphasis on the gastrointestinal tract and liver: An update. Hepatology 9:126–138, 1989
Jensen LS, Krarup N, Larsen JA, Juhl C, Nielsen TH, Dybdahl H: Effect of endoscopic sclerotherapy of esophageal varices on liver blood flow and liver function. Scand J Gastroenterol 22:619–626, 1987
Juhl CO, Jensen LS, Steiniche T, Moussa E: Recombinant human epidermal growth factor prevents sclerotherapy-induced esophageal ulcer and stricture formations in pigs. Dig Dis Sci 39:393–401, 1994
Jensen LS, Krarup N, Larsen JA, Juhl C, Nielsen TH: Effect of acute portal hypertension on hepatosplanchnic hemodynamics and liver function. Scand J Gastroenterol 22:463–470, 1986
Weibel ER: Stereological Methods. Practical Methods for Biological Morphometry. New York, Academic Press, 1980
Nexø E, Jørgensen PE, Hansen MR: Human epidermal growth factor—on molecular forms present in urine and blood. Regul Pept 42:75–84, 1992
Banks-Schlegel SP, Quintero J: Human esophageal carcinoma cells have fewer, but higher affinity epidermal growth factor receptors. J Biol Chem 261:4359–4362, 1986
Sarin SK, Nanda R, Anand BS: Oesophageal ulceration after sclerotherapy—a complication or an accompaniment? Endoscopy 18:44–45, 1986
Kochhar R, Goenka MK, Mehta SK: Esophageal strictures following endoscopic variceal sclerotherapy. Antecedents, clinical profile, and management. Dig Dis Sci 37:347–352, 1992
Gregory PB: Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 324:1779–1784, 1991
Tyson LM, Browne CA, Jenkin G, Thorburn GD: The fate and uptake of murine epidermal growth factor in the sheep. J Endocrinol 123:121–130, 1989
Jørgensen PE, Poulsen SS, Nexø E: Distribution of i.v. administered epidermal growth factor in the rat. Regul Pept 23:161–169, 1988
Olsen PS, Poulsen SS, Kirkegaard P, Nexø E: Role of submandibular saliva and epidermal growth factor in gastric cytoprotection. Gastroenterology 87:103–108, 1984
Olsen PS, Poulsen SS, Therkelsen K, Nexø E: Effect of sialoadenectomy and synthetic human urogastrone on healing of chronic gastric ulcers in rats. Gut 27:1443–1449, 1986
Brzozowski T, Majka J, Garlicki J, Drozdowicz D, Konturek SJ: Role of polyamines and prostaglandins in gastroprotective action of epidermal growth factor against ethanol injury. J Clin Gastroenterol 13:S98-S102, 1991
Olsen PS, Poulsen SS, Therkelsen K, Nexø E: Oral administration of synthetic human urogastrone promotes healing of chronic duodenal ulcers in rats. Gastroenterology 90:911–917, 1986
Jaeger LA, Lamar CH, Cline TR, Cardona CJ: Immunolocalization of epidermal growth factor (EGF) and EGF receptors in the porcine upper gastrointestinal tract. Am J Vet Res 53:1685–1692, 1992
Jankowski J, Murphy S, Coghill G, Grant A, Wormsley KG, Sanders DSA, Kerr M, Hopwood D: Epidermal growth factor receptors in the oesophagus. Gut 33:439–443, 1992
Dutta SK, Orestes M, Vengulekur S, Kwo P: Ethanol and human saliva: effect of chronic alcoholism on flow rate, composition, and epidermal growth factor. Am J Gastroenterol 87:350–354, 1992
Harris RC, Hoover RL, Jacobson HR, Badr KF: Evidence for glomerular actions of epidermal growth factor in the rat. J Clin Invest 82:1028–1039, 1988
Gan BS, MacCannell KL, Hollenberg MD: Epidermal growth factor-urogastrone causes vasodilatation in the anesthetized dog. J Clin Invest 80:199–206, 1987
Author information
Authors and Affiliations
Additional information
This study was partially funded from Gastrone Corporation, Menlo Park, California; and the Institute of Experimental Clinical Research, Aarhus, Denmark.
Rights and permissions
About this article
Cite this article
Juhl, C.O., Vinter-Jensen, L., Jensen, L.S. et al. Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs. Digest Dis Sci 39, 2671–2678 (1994). https://doi.org/10.1007/BF02087708
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02087708